Astros, Verlander Agree to Return Engagement
The last time we saw Justin Verlander pitch, he looked like his usual, dominant self. In six innings against Seattle, he allowed only three hits and two runs while striking out seven. As had been the case in his Cy Young season, he was a little dinger-prone, surrendering two blasts to an otherwise overmatched Mariners lineup. But in an Opening Day start played in unusual circumstances, his stuff looked as sharp as ever.
Unfortunately, that last outing was in July of 2020. Within the week, Verlander landed on the injured list with a forearm strain. Two months later, the future Hall of Famer announced that he was undergoing Tommy John surgery. The procedure sidelined him for all of 2021, his last season prior to reaching free agency.
The timing gave the Astros a difficult decision. With no recent performance to evaluate, Houston nonetheless extended their ace a qualifying offer, which forced Verlander to pick between testing a very uncertain free agent market and taking a $10 million pay cut. He ultimately turned down the QO, but not the Astros themselves. In news amusingly broken by his brother Ben, Verlander re-signed with Houston yesterday on a one-year, $25 million deal that includes a $25 million player option for a second year.
A reunion between player and club suits both parties. We don’t know whether Verlander is in the twilight of his career just yet: age is just a number for pitchers, and prior to the injury, JV was one of the game’s very best hurlers. Still, it’s reasonable to assume that he’s at least near the end of his career, and if he wants to get the most out of his remaining years, it makes sense to enter a potential bounce-back season with as few distractions and new hurdles as possible. Staying put should help facilitate that. Houston has been his in-season home for more than four years now, and with the notable exception of Brent Strom’s departure, the Astros remain as well-resourced as ever. Heading into an uncertain campaign, Verlander is about as well-positioned as he could be to return to form.
The fit is perhaps even better on the team’s side, which may seem odd on the surface because Houston already has several good starters. Even if Zack Greinke leaves, as seems likely, Houston returns Lance McCullers Jr., Luis Garcia, Framber Valdez, José Urquidy, and Jake Odorizzi, a group that made 121 starts last year. Lurking in the wings are Cristian Javier, a talented arm who opened last season in the rotation, and Hunter Brown, a Top 100 prospect who reached Triple-A last season. The depth here is enviable:
| Name | Starts | ERA | FIP | xFIP | WAR |
|---|---|---|---|---|---|
| Lance McCullers Jr. | 28 | 3.16 | 3.52 | 3.69 | 3.3 |
| Luis Garcia | 28 | 3.30 | 3.63 | 3.93 | 3.1 |
| Framber Valdez | 22 | 3.14 | 4.01 | 3.58 | 1.9 |
| José Urquidy | 20 | 3.62 | 4.14 | 4.38 | 1.8 |
| Jake Odorizzi | 23 | 4.21 | 4.48 | 4.82 | 1.1 |
| Cristian Javier | 9 | 3.55 | 4.43 | 4.35 | 0.7 |
But if Houston’s World Series loss came with a broader lesson, it would be about the limitations of a pitching staff light on frontline arms and dependable innings eaters. Of the returning starters, only McCullers topped 160 innings, and even he only averaged 17 outs per start. He also missed the World Series with a forearm injury, the latest in a long line of maladies that have limited him to just 671 frames since his debut in 2015. Garcia, Valdez, and Urquidy all project as quality mid-rotation arms but none of them have ever carried a starter’s workload for a full year and all of them had massive innings jumps in 2021. For all their depth, Houston doesn’t currently have a true No. 1 on the roster.
Verlander could again assume that mantle. In his last full season, the righty notched a 2.58 ERA and 3.27 FIP across 223 innings (a total that would have led the majors in 2021). In that season, opponents hit .171 against him. He struck out a career-high 35.4% of hitters he faced, and he only walked 4.8% — his second-best mark, trailing only the 4.4% he registered in 2018. Those numbers came alongside steady velocity across the board. The Astros may not need a starter. But if Verlander can offer anything close to that production again in 2021, nobody will be stressing too much about where Odorizzi, Javier, and Urquidy fall in the rotation’s pecking order.
There is a bit of risk involved. The money isn’t a huge issue, as the Astros can afford to pay $25 million for a gilded flier. They’re still $30 million away from incurring luxury tax penalties even after counting Verlander’s salary, and that’s assuming the tax threshold doesn’t increase in this winter’s collective bargaining negotiations; 2023 looks even more scant, though of course free agent signings could change that.
There are a couple of orange flags in Verlander’s profile, however, even dating back to 2019. The first is home runs. His 1.45 HR/9 ratio was, even in the juiciest ball season, pretty darn high. Some of that can be brushed aside with nods to the ball and a stratospheric HR/FB%. But there are reasons to worry he’ll be vulnerable to the long ball again. Verlander had elite spin rates and movement profiles in 2018 and ’19. In theory, that’s a good thing, but it’s notable that both the movement and the spin were significantly better following his trade to Houston from Detroit in 2017. We can’t say for sure whether he was using a little of the sticky, but if he was, some of the tools at his disposal back then are (in theory) not available to him now. That’s not a great development for someone looking to give up fewer homers.
There’s also the uncertainty surrounding Verlander’s return from the shelf. For as dominant as he’s been throughout his career, Verlander is no spring chicken. He will be 39 on Opening Day, and he’s coming off of a major surgery. He had the procedure done at the age of 37, and according to John Roegele’s Tommy John database, that makes him the sixth oldest pitcher (and second oldest starter) to undergo that particular operation. Even if we include a few other 37-year-olds to enlarge the sample, the track record of pitchers coming back from Tommy John at his age or older is pretty grim viewing:
| Name | Age at surgery | Pre-surgery career ERA+ | Post-surgery IP | Post-surgery ERA+ |
|---|---|---|---|---|
| Jamie Moyer | 47 | 104 | 53.2 | 82 |
| John Franco | 41 | 144 | 95.1 | 93 |
| Joe Nathan | 40 | 150 | 6.1 | ∞ |
| Jose Contreras | 40 | 101 | 5 | 43 |
| Rafael Betancourt | 38 | 140 | 39.1 | 75 |
| Mike Fetters | 38 | 120 | 18.2 | 54 |
| Justin Verlander | 37 | — | — | — |
| Bronson Arroyo | 37 | 103 | 71 | 61 |
| Arthur Rhodes | 37 | 104 | 176.2 | 154 |
| Gary Lavelle | 37 | 129 | 32 | 77 |
Shoutout to Arthur Rhodes.
We can’t just assume that Verlander will stumble in his return like previous elder arms: He’s a different pitcher, with a different body and presumably a more sophisticated rehab than the names listed above. But we also have to acknowledge the possibility that elbow surgery — a potential inflection point at the best of times — is a dicier proposition than usual at his age. A return to form is possible, but there’s also a chance that he’s done as an effective pitcher. There’s plenty of upside for Houston here, but in targeting Verlander, the opportunity cost is that the Astros are foregoing a safer option, and could end up with a diminished version of him for a year more if he exercises his option.
At the end of the day though, there’s risk in any move. Even if Verlander is a shadow of his former self, the Astros have a good enough roster to win the AL West. If he is effective, Houston likely enters October as one of the two or three favorites for the title. The terms of the deal are steeper than we anticipated in our recent ranking of the top 50 free agents (Verlander checked in at No. 19), particularly when you consider the option, but Houston is presumably aware of the possibility of him turning into a pumpkin. Ultimately, Verlander gets to return to his old stomping grounds and Houston could be getting an ace at a discount. Everyone should be happy here.
Brendan covers prospects and the minor leagues for FanGraphs. Previously he worked as a Pro Scout for the Pittsburgh Pirates.
The market for Verlander had to be very, very good. The Astros basically had to guarantee him $50M whether he throws a single pitch for them or not, but if he’s good in 2022, he can opt out and go for more money as a free agent. The Astros have assumed all the risk at a high AAV. I’m not questioning the decision, just noting he must have been receiving very strong interest from other teams for the Astros to extend this type of offer.
Considering the interest Syndergaard received, also after missing two years (while young), and never reaching the highs that Verlander has reached, yeah, I’m guessing the interest in Verlander was probably very strong throughout the league.
Potential Cy Young winners don’t get to FA all that often…
Are you saying the “while young” is a positive or negative? Do you view Syndergaard as similarly likely to win CYA?
In previous offseasons, I’ve argued that opt-outs are really worth nothing to a team because they often come late enough in the contract that if they do opt out, you get all the benefit without the downside (and if they don’t opt-out, it doesn’t change things). But when you see deals like this, you can see how the use of them has changed. It’s less a pillow deal and more of a deal that is ensured so that no matter what, Verlander can’t lose it. We’ve seen deals like this before, but it is wild for a guy who hasn’t pitched in two years to get it.
I am having a tough time with the reasoning behind the massive contracts, albeit short term, for two pitchers who have combined to throw 8 innings in 2 years, and this in a game that is rapidly lessening the importance of starting pitching. Desperation is likely the most logical answer. The only other choices seem to be incompetence or insanity.
Maybe teams don’t value $/WAR linearly and the risk/reward for an ace is worth it to them?
What other options do they have for a potential ace?
I think that your response affirms my thesis. They are desperate for anybody and I mean any body that can possibly lift their arm off the ground. From a risk reward valuation these signings make little or no sense. With even the top of the rotation pitchers being limited to twice through the order the cost of starters should be dropping. Especially for wildly risky types such as Verlander, age 39, and Syndergaard, who gave up a hit an inning in his last full season and is hinting that the decline may have already begun.
Really curious where Verlander’s projections end up.
Looking at last year’s leaderboard, something approximating Lance McCullers season – 160 IP around a 75 to 80 ERA/FIP minus shaking out to like 3.5 to 4.5 WAR – seems about right for JV in 2022, er no?
They’d be very happy with the 160 IP. Even 100 IP plus playoffs is probably worth it
I would be stunned to see Verlander project for that level of production, after having not pitched for (virtually) two seasons and be 39.
These deals for pitchers coming off major injuries seem crazy to me. It’ll be interesting to see where the dollars to projected WAR ends up.
I get that part of the reason why Verlander and Syndergaard got those deals is because they’ve had big seasons before their injuries, but between these and the Berrios deal it certainly seems like the price of pitching is as high as ever. The E-Rod deal is more in line with what I expected, but I didn’t see the opt-out and that isn’t cheap.
Every offseason it seems like there are predictions that this is the year that teams will stop spending so much money, and then the offseason starts and all the owners complaining about how their losing so much money looks quite hollow. It’s like they desperately want to collude but they don’t know how.
This is purely speculation, but it has seemed like TJS in specific has been much less damaging for pitchers in recent years. Maybe it’s better rehab regimens, maybe the surgery is less invasive nowadays, but it sure seems like pitchers aren’t much different before and after TJS.
Maybe teams just really value the chance to get a top-line starter without having to sign a 6-8 year deal. If they get 5-6 win vintage Verlander, obviously it’s fabulous. The potential to get absolutely nothing for that $50m would scare me, though.
The Astros fear of term is just so stark. They’re willing to pay $25m for a 37-year old coming off TJ if its short term, but will low-ball Correa on term despite him being a 27-year old,
Anyway, really curious how he comes back. Given they’ll likely limit his load it could be a great boost to the rotation later in the year.
Stros also have much greater insight into the health of both of those guys than any other team. Correa’s back is an ongoing concern and it sounds like it took a lot of in season work to ensure he made it through the entire year…at 26 years old (though I’m sure the team leaked this to see if they could drive his market down at all).
I still think Correa is the top SS on the market and should be a top 5 player at the position for years yet when healthy, but I can also see why a team would be hesitant to give him 10 years at a premium AAV.
The Astros act like the total debt matters as if they were pushing up against the debt service rule or trying to maintain flexibility under the debt service rule assuming future salaries count as debt.
I can’t be the only person that just isn’t putting any stock in that graph, right? I do appreciate the effort of finding the pitchers that have some relationship to Verlander’s situation, but there really is nothing I feel like you can glean from this. The first four names were at least 40 when they HAD the surgery, which means 41 or 42 when coming back.
None of these guys had the career that Verlander has had and none of them were among the very best pitchers in baseball when they went under the knife. Of course there is a lot of risk here. I think we can all intuitively feel that there is a ton of risk here. I just don’t think these comps are telling us anything.
On another note, the Braves extension of Charlie Morton is looking pretty damn fine right now. He’s also no Verlander, but looking at the deals for pitchers so far this month and then his $20 million with a team option for 2023, that looks great for the Braves. Of course it should be noted that the Braves may have been negotiating only with retirement, but that doesn’t change the fact they got a great deal for Morton.
I think the list shows that this just isn’t done too often at this age. The comps don’t mean much but again it shows that there is a lot of risk in the unknown.
What that list shows is there aren’t any comps.
I literally only clicked on this article because I was curious if any starters had ever had TJS at his age. Major arm injury generally means retirement after age 35 or so.
Being over 35, by itself, generally means retirement.
This is why I don’t put any stock in clickbait tweets, etc talking about a strained relationship between a player and a team.
I’m guessing most or all of the oldsters on this list had TJ before umbilical cord T-cell therapties were so available, and the leading doctor-scientist in that field is in Houston.
Shoutout indeed to Arthur Rhodes. Teammate of both Lance Lynn and Dwight Evans during his MLB career.
From 06-08 Verlander pitched with Kenny Rogers, who was born in 1964 and debuted in 1989.
Kenny Rogers pitched with Nolan Ryan who was born in 1947 and debuted in 1966.
In 2021 Verlander will pitch with Cristian Javier who was born in 1997 and Luis Garcia born in ’96.
If Javier or Luis Garcia pitch 15 seasons they will almost certainly pitch with someone born after 2012.
$50m guaranteed? Wow. As for the Angels, figuring the cost of the pick plus what bonus pool money ends up being worth on average, they paid almost $30 million for 120-140 innings of Syndergaard’s time. Even at his best–in just two years of seven–he was barely worth that.
Slice the data just so and Noah has all of one (!) season with 155 innings and a league average ERA. I wonder what’s up with the Angels and money in 2023 and beyond that they’re not signing someone like Gausman, who projects to be better than Noah in 2022, for significantly less money.
Strange days indeed.